

## REFERENCES

1. D'Onfrio G, Jauch E, Jagoda A, et al: Opportunities to advance research on neurological and psychiatric emergencies. *Ann Emerg Med* 56: 551, 2010. [PMID: 21063295]
2. Lukens T, Wolf S, Edlow J, et al: Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. *Ann Emerg Med* 47: 79, 2006. [PMID: 16387222]
3. Zimbroff D: Pharmacological control of agitation: focus on intramuscular preparations. *CNS Drugs* 22: 199, 2008. [PMID: 18278976]
4. Cummings M, Miller B: Pharmacologic management of behavioral instability in medically ill pediatric patients. *Curr Opin Pediatr* 16: 516, 2004. [PMID: 15367845]
5. Foster S, Kessel J, Berman M, et al: Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. *Int J Psychopharmacol* 12: 175, 1997. [PMID: 9248875]
6. Currier G, Simpson G: Risperidone liquid concentrate and oral lorazepam versus intramuscular lorazepam for treatment of psychotic agitation. *J Clin Psychiatry* 62: 153, 2001. [PMID: 11305699]
7. Lim H, Kim J, Pae C, et al: Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. *Neuropsychobiology* 62: 81, 2010. [PMID: 20523078]
8. Hsu W, Huang S, Lee B, et al: Comparison of intramuscular olanzapine, oral disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. *J Clin Psychopharmacol* 30: 230, 2010 [PMID: 20473506]
9. Rautaharju P, Surawicz B, Gettes L: AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram. *Circulation* 119: e241, 2009. [PMID: 19281931]
10. Johnson JN, Ackerman MJ: QTc: how long is too long? *Br J Sports Med* 43: 657, 2009. [PMID: 19734499]
11. Yap YG, Camm AJ: Drug-induced QT prolongation and torsades de pointes. *Heart* 89: 1363, 2003. [PMID: 14594906]
12. Roden DM: Drug-induced prolongation of the QT interval. *N Engl J Med* 350: 1013, 2004. [PMID: 14999113]
13. Stahl S: Anxiolytics and sedative-hypnotics. In: *Essential Psychopharmacology, Neuroscientific Basis and Practical Applications*, 2nd ed. Cambridge, United Kingdom: Cambridge University Press, 2000:297–333.
14. Battaglia J: Pharmacological management of acute agitation. *Drugs* 65: 1207, 2005. [PMID: 15916448]
15. DeFrydt J, Demeyenaere K: Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. *Eur Psychiatry* 19: 243, 2004. [PMID: 15276655]
16. <http://www.merckmanuals.com/professional/lexicomp/lorazepam.html>. (Lorazepam. Lexi-Comp drug information [by subscription].) Accessed October 7, 2011.
17. Battaglia J, Moss S, Rush J, et al: Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. *Am J Emerg Med* 15: 335, 1997. [PMID: 9217519]
18. [www.fda.gov](http://www.fda.gov). (Inapsine [droperidol]: Dear healthcare professional letter Dec 2001.) Accessed November 16, 2011.
19. Meyer-Massetti C, Cheng C, Sharpe B, et al: The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? *J Hosp Med* 5: E8, 2010. [PMID: 20394022]
20. Picard L, Lindsay S, Strawn J, et al: Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. *Pharmacotherapy* 28: 530, 2008. [PMID: 18363536]
21. [www.fda.gov](http://www.fda.gov). (Information for healthcare professionals: haloperidol [marketed as Haldol, Haldol Decanoate and Haldol Lactate].) Accessed November 16, 2011.
22. Altamura AC, Sassella F, Santini A, et al: Intramuscular preparations of antipsychotics uses and relevance in clinical practice. *Drugs* 63: 493, 2003. [PMID: 12600227]
23. <http://www.merckmanuals.com/professional/lexicomp/fluphenazine.html>. (Fluphenazine. Lexi-Comp drug information [by subscription].) Accessed May 14, 2012.
24. Ahmed U, Jones H, Adams C: Chlorpromazine for psychosis-induced agitation or aggression. *The Cochrane Library*. Published Online December 8, 2010. (<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007445.pub2/abstract>).
25. [www.fda.gov](http://www.fda.gov). (Information on conventional antipsychotics. Chlorpromazine.) Accessed December 14, 2011.
26. Devlin J, Roberts R, Fong J, et al: Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. *Crit Care Med* 38: 419, 2010. [PMID: 19915454]
27. Hatta K, Kawabata T, Yoshida K, et al: Olanzapine orally disintegrating tablet vs risperidone oral solution in the treatment of acutely agitated psychotic patients. *Gen Hosp Psychiatry* 30: 36, 2008. [PMID: 18585542]
28. Breier A, Meehan K, Birkett M, et al: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. *Arch Gen Psychiatry* 59: 441, 2002. [PMID: 11982448]
29. [www.lilly.ca](http://www.lilly.ca). (Dear Healthcare Professional. Important safety information regarding the correct use of Zyprexa intramuscular.) Accessed September 7, 2004.
30. Zyprexa (olanzapine) product information. Indianapolis, IN: Eli Lilly and Co; June 2011.
31. Brook S: Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. *J Clin Psychiatry* 64(Suppl 19): 13, 2003. [PMID: 14728085]
32. Daniel D, Potkin S, Reeves K, et al: Intramuscular ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. *Psychopharmacology* 155: 128, 2001. [PMID: 11401000]
33. Geodon (ziprasidone) product information. New York, NY: Pfizer Inc.; December 2010.
34. Andrezina R, Josiassen R, Marcus R, et al: Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. *Psychopharmacology* 188: 281, 2006. [PMID: 16953381]
35. Abilify (aripiprazole) product information. Japan, Tokyo: Otsuka Pharmaceutical Co, Ltd.; February 2011.
36. Sonnier L, Barzman D: Pharmacologic management of acutely agitated pediatric patients. *Pediatr Drugs* 13: 1, 2011. [PMID: 21162596]
37. Wan RYY, Kasliwal M, McKenzie CA, Barrett NA: Quetiapine in refractory hyperactive and intensive care mixed delirium: a case series. *Crit Care* 15: R159, 2011. [PMID: 21711554]
38. Adimando AJ, Poncin YB, Baum CR: Pharmacologic management of the agitated pediatric patient. *Pediatr Emerg Care* 26: 856, 2010. [PMID: 21057285]
39. Megna J, Devitt P, Sauro M, et al: Gabapentin's effect on agitation in severely and persistently mentally ill patients. *Ann Pharmacother* 36: 12, 2002. [PMID: 11816241]
40. Letterman L, Markowitz J: Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. *Pharmacotherapy* 19: 565, 1999. [PMID: 10331819]
41. Bowden C, Swann A, Calabrese J, et al: A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in treatment of acute mania. *J Clin Psychiatry* 67: 1501, 2006. [PMID: 17107240]
42. Reade M, O'Sullivan K, Bates S, et al: Dexmedetomidine versus haloperidol in delirious, agitated, intubated patients: a randomized, open-label trial. *Crit Care* 13: R75, 2009. [PMID: 19454032]
43. Schneider L, Tarot P, Dagerman K, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med* 355: 1525, 2006. [PMID: 17035647]
44. Kohen I, Preval H, Southard R, et al: Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly adults: retrospective findings from a psychiatric emergency service. *Am J Geriatr Pharmacother* 3: 240, 2005. [PMID: 16503319]
45. Fick D, Cooper J, Wade W, et al: Updating the beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. *Arch Intern Med* 163: 2716, 2003. [PMID: 14662625]
46. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM: Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). *Br J Addict* 84: 1353, 1989. [PMID: 2597811]
47. Chang F: Strategies for benzodiazepine withdrawal in seniors. *CPJ* 138: 38, 2005.

## USEFUL WEB RESOURCES

FDA Drug Safety Communications Page—<http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm>  
Drugs@FDA (product labeling, pharmacology, pharmacokinetics)—<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/>